BioLife Solutions, Inc. (BLFS)

BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter and full year financial results will be released on February 26, 2026.

BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $25.12 and traded as low as $21.96. BioLife Solutions shares last traded at $22.67, with a volume of 687,757 shares trading hands.

The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.

Campbell and CO Investment Adviser LLC raised its stake in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) by 160.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,533 shares of the medical equipment provider's stock after

BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Generation Alpha (OTCMKTS:GNAL - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk. Analyst Ratings This is a summary of recent

Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million exceeded the high end of the previously raised guidance range for FY 2025 BOTHELL, Wash., Jan. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc.  (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced preliminary fourth quarter and full year 2025 unaudited revenue from continuing operations.

Envista (NYSE: NVST - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Risk and Volatility Envista has a beta of 0.99,

Terumo (OTCMKTS:TRUMY - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Ratings This is a summary of recent ratings

The CFO sold 30,000 shares for $771,600. This transaction represented 16.4% of Wichterman's direct holdings, reducing his direct stake to 152,769 shares.

Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in BioLife Solutions, Inc. (NASDAQ: BLFS) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 9,524 shares of the medical equipment provider's stock, valued at approximately $205,000. Several other hedge

New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , Nov. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J.

Campbell and CO Investment Adviser LLC bought a new stake in BioLife Solutions, Inc. (NASDAQ: BLFS) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 13,256 shares of the medical equipment provider's stock, valued at approximately $286,000. A number of other

The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December: Raymond James Napa Small Cap Symposium November 17, 2025 Napa Valley at The Meritage Stephens Annual Investment Conference November 18-20, 2025 Nashville at the Grand Hyatt Nashville Jefferies Global Healthcare Conference November 17-20, 2025 London at The Waldorf Hilton Furey Research Partners Hidden Gems Conference November 24-25, 2025 Virtual Wolfe Research Small & Mid-Cap Conference December 2-3, 2025 Virtual Northland Growth Conference 2025 December 16, 2025 Virtual The BioLife Solutions Investor Presentation, reflecting the recently refreshed corporate branding, is now available on the Investor Relations section of the company's website.